These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
75 related articles for article (PubMed ID: 6412489)
21. Antibodies to proteases and exotoxin A of Pseudomonas aeruginosa in patients with cystic fibrosis: Demonstration by radioimmunoassay. Klinger JD; Straus DC; Hilton CB; Bass JA J Infect Dis; 1978 Jul; 138(1):49-8. PubMed ID: 98596 [TBL] [Abstract][Full Text] [Related]
22. Multi-valent human monoclonal antibody preparation against Pseudomonas aeruginosa derived from transgenic mice containing human immunoglobulin loci is protective against fatal pseudomonas sepsis caused by multiple serotypes. Lai Z; Kimmel R; Petersen S; Thomas S; Pier G; Bezabeh B; Luo R; Schreiber JR Vaccine; 2005 May; 23(25):3264-71. PubMed ID: 15837231 [TBL] [Abstract][Full Text] [Related]
23. Exotoxins of Pseudomonas aeruginosa. 3. Characteristics of antitoxin A. Liu PV; Hsieh H J Infect Dis; 1973 Oct; 128(4):520-6. PubMed ID: 4200593 [No Abstract] [Full Text] [Related]
24. Systematic generation of antigen specific human monoclonal antibodies with therapeutical activities using active immunization. Lang AB; Fürer E; Senyk G; Larrick JW; Cryz SJ Hum Antibodies Hybridomas; 1990; 1(2):96-103. PubMed ID: 2129420 [TBL] [Abstract][Full Text] [Related]
25. Comparative studies on the protective potential of antisera directed against four antigenic preparations from Pseudomonas aeruginosa. Johnston LJ; Syeklocha D Can J Microbiol; 1972 Oct; 18(10):1607-11. PubMed ID: 4628185 [No Abstract] [Full Text] [Related]
26. Active and passive immunization strategies for Pseudomonas aeruginosa pneumonia. Pennington JE; Pier GB; Sadoff JC; Small GJ Rev Infect Dis; 1986; 8 Suppl 4():S426-33. PubMed ID: 2944209 [TBL] [Abstract][Full Text] [Related]
27. Salmonella Typhimurium strain expressing OprF-OprI protects mice against fatal infection by Pseudomonas aeruginosa. Zhang M; Sun C; Gu J; Yan X; Wang B; Cui Z; Sun X; Tong C; Feng X; Lei L; Han W Microbiol Immunol; 2015 Sep; 59(9):533-44. PubMed ID: 26249788 [TBL] [Abstract][Full Text] [Related]
28. [Antigenic properties of Pseudomonas aeruginosa anatoxin and the protective action of antitoxic anti-Pseudomonas aeruginosa serum]. Podgornaia LG; Dziuban NF Zh Mikrobiol Epidemiol Immunobiol; 1986 Jun; (6):67-9. PubMed ID: 3092510 [TBL] [Abstract][Full Text] [Related]
29. Production and characterization of a human hyperimmune intravenous immunoglobulin against Pseudomonas aeruginosa and Klebsiella species. Cryz SJ; Fürer E; Sadoff JC; Fredeking T; Que JU; Cross AS J Infect Dis; 1991 May; 163(5):1055-61. PubMed ID: 1902245 [TBL] [Abstract][Full Text] [Related]
30. [Isolation and study of the properties of a polyvalent corpuscular Pseudomonas aeruginosa vaccine. An evaluation of the biological properties of a polyvalent corpuscular Pseudomonas aeruginosa vaccine]. Ttitova TI; Grigor'ev NI; Antsiferova NG; Radkevich SA; Moroz AF Zh Mikrobiol Epidemiol Immunobiol; 1985 Jul; (7):14-8. PubMed ID: 3931392 [TBL] [Abstract][Full Text] [Related]
31. Protective activity of an intravenous immune globulin (human) enriched in antibody against lipopolysaccharide antigens of Pseudomonas aeruginosa. Collins MS; Roby RE Am J Med; 1984 Mar; 76(3A):168-74. PubMed ID: 6424446 [TBL] [Abstract][Full Text] [Related]
32. A polyvalent human gamma-globulin immune to Pseudomonas aeruginosa: passive protection of mice against lethal infection. Fisher MW J Infect Dis; 1977 Aug; 136 Suppl():S181-5. PubMed ID: 70492 [TBL] [Abstract][Full Text] [Related]
33. Antibody responses induced by long-term vaccination with an octovalent conjugate Pseudomonas aeruginosa vaccine in children with cystic fibrosis. Zuercher AW; Horn MP; Que JU; Ruedeberg A; Schoeni MH; Schaad UB; Marcus P; Lang AB FEMS Immunol Med Microbiol; 2006 Jul; 47(2):302-8. PubMed ID: 16831219 [TBL] [Abstract][Full Text] [Related]
35. Use of passive immunotherapy in the treatment of experimental Pseudomonas aeruginosa infections in burns. Neely AN; Holder IA Antibiot Chemother (1971); 1987; 39():26-40. PubMed ID: 3118788 [No Abstract] [Full Text] [Related]
36. Protective activity of antibodies to exotoxin A and lipopolysaccharide at the onset of Pseudomonas aeruginosa septicemia in man. Pollack M; Young LS J Clin Invest; 1979 Feb; 63(2):276-86. PubMed ID: 429553 [TBL] [Abstract][Full Text] [Related]
37. The prophylactic effects of human IgG derived from sera containing high anti-PcrV titers against pneumonia-causing Pseudomonas aeruginosa. Kinoshita M; Kato H; Yasumoto H; Shimizu M; Hamaoka S; Naito Y; Akiyama K; Moriyama K; Sawa T Hum Vaccin Immunother; 2016 Nov; 12(11):2833-2846. PubMed ID: 27454613 [TBL] [Abstract][Full Text] [Related]
38. [Immunologic study of artificial complex antigens obtained from P. aeruginosa lipopolysaccharides]. Edvabnaia LS; Stanislavskiĭ ES; Kolker II; Grishina IA; Zarubina EK Zh Mikrobiol Epidemiol Immunobiol; 1979 Sep; (9):36-41. PubMed ID: 115186 [TBL] [Abstract][Full Text] [Related]
39. Properties determining the potential of naturally occurring and vaccine-induced human antibodies to protect against lethal infection of Pseudomonas aeruginosa. Bruderer U; Fürer E; Cryz SJ; Lang AB Res Immunol; 1992 Feb; 143(2):165-74. PubMed ID: 1374194 [TBL] [Abstract][Full Text] [Related]
40. [Evaluation of the specific activity of hyperimmune anti-Pseudomonas aeruginosa human plasma in an experiment]. Podgornaia LG; Shinkarenko AA; Krokhina MA; Dziuban NF; D'iachenko VF Patol Fiziol Eksp Ter; 1987; (2):70-2. PubMed ID: 3112715 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]